From FASTQ to Biological Truth

PrecisionGEN provides end-to-end, physician-scientist–led genomics consulting that turns complex data into clear, clinical decisions. We take your data from raw sequence through interpretation and validation — delivering clear, actionable insights where standard pipelines stop.

Explore Services Request Consultation

Years in clinical genomics

Exomes & genomes

11+

Novel disease genes discovered

Global

US • Europe • MENA

Our Philosophy: Ending the Diagnostic Odyssey

Genomics has unlocked vast amounts of data — but too often, that data fails to deliver answers. Patients with rare diseases and complex cancers endure a painful "diagnostic odyssey" of inconclusive tests and ambiguous results. Standard pipelines generate reports, but not resolution.

At PrecisionGEN, our philosophy is simple: The search doesn't end until the biology is clear. We integrate clinical reasoning, multi-omics expertise, and functional validation strategies to transform raw data into biological truth. Our mission is to deliver the definitive answer that powers your next discovery, secures your next grant, or solves your most challenging clinical case.

Precision Genomics Services

End‑to‑end analysis, multi‑omics integration, and decisive interpretation.

🧬

End-to-End Genomic Analysis

WES, WGS (short & long‑read), QC, alignment, variant calling, and expert interpretation for diagnostics and R&D.

Benefit: One trusted partner for a coherent, accurate result.

🔬

Multi‑Omics Integration

RNA‑seq, splicing & fusions, methylation, epigenomics—integrated with DNA for mechanism and biomarkers.

Benefit: Reveal drivers DNA‑only pipelines miss.

🎯

Variant Characterization & Validation

VUS reclassification, splicing/non‑coding interpretation, and functional strategies (exon‑trap, reporters, CRISPR).

Benefit: Convert ambiguity into clinical‑grade proof.

📈

Strategic R&D Support

Target validation, biomarker discovery, pipeline audits, and integrative analysis for publications and grants.

Benefit: Increase yield, de‑risk programs, move faster.

How We Work: A Clear Path from Inquiry to Insight

Confidential Consultation & Scoping

We start with a confidential, no-obligation call to understand your challenge, data, and goals. You then receive a clear, fixed-fee proposal and Statement of Work.

Integrated Analysis & Review

Once approved, our physician-scientist team manages the entire analytical journey. We provide regular updates and collaborate with your team to ensure perfect alignment.

Actionable Reporting & Debrief

We deliver a comprehensive report that provides a clear biological narrative and actionable insights. Every project concludes with a live debrief to discuss findings and next steps.

Who We Serve

🏢

Biopharma

De-risk your drug development with deep biological validation for targets, biomarkers, and companion diagnostic strategies.

🧪

Clinical Labs

Increase diagnostic yield without expanding headcount — on-demand expert review and pipeline audits.

🎓

Academic Researchers

Translate complex multi-omics datasets into publications and funded proposals through integrative analysis and storytelling.

Suleyman Gulsuner, MD, PhD

Physician-scientist bridging clinical medicine and computational genomics

About the Founder

✓15,000+ exomes/genomes interpreted
✓11+ novel disease genes discovered
✓ Pioneer in long-read sequencing and RNA integration for diagnostics
✓ Developer of the cBROCA targeted RNA-seq panel for splicing analysis
✓ Achieved high diagnostic yields in unsolved rare disease and cancer cases
✓ NIH & DoD‑funded work across diverse populations

Key Publications

Selected publications demonstrating our core expertise.

Foundational Science & Gene Discovery

2020

Neurogenetics WES/WGS

Genetics of schizophrenia in the South African Xhosa

Science | ⭐ Lead Author

Reveals that ultra-rare, damaging mutations in synaptic genes contribute significantly to schizophrenia risk, demonstrating the power of studying diverse populations to uncover novel disease biology.

2013

Neurogenetics WES/WGS + RNA-Seq

Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network

Cell | ⭐ Co-first Author

A landmark study that integrated genomics and transcriptomics to prove that genes carrying *de novo* mutations in schizophrenia form a functional network critical for fetal brain development.

Advanced Genomics in Hereditary Cancer

2024

Cancer Genetics Long-Read + RNA-Seq

Long-read DNA and cDNA sequencing identify cancer-predisposing deep intronic variation...

Genome Research | ⭐ Lead Author

Demonstrates the core value of PrecisionGEN: using a robust platform of long-read DNA and RNA sequencing to find cryptic, pathogenic deep intronic variants in major cancer genes that conventional methods miss.

2019

Cancer Genetics RNA-Seq/Splicing

Characterization of splice-altering mutations in inherited predisposition to cancer

PNAS | ⭐ Co-first Author

Established a systematic framework for using RNA analysis to characterize and functionally validate splice-altering mutations in cancer genes, turning ambiguous DNA findings into definitive answers.

Solving Rare & Complex Neurological Disorders

2025

Neurogenetics Long-Read Sequencing

Unstable FGF14 GAA Repeat Expansions in Indian ataxia patients...

Journal of Human Genetics

A recent collaborative study characterizing complex GAA repeat expansions in ataxia and identifying potential genetic modifiers using advanced long-read sequencing in a diverse Indian cohort.

2011

Rare Disease Gene Discovery

Homozygosity mapping and targeted genomic sequencing reveal the gene responsible for cerebellar hypoplasia...